In- and out-licensing evaluation

We help you to identify, qualify, and prioritize possible in- and out-licensing evaluation candidates and evaluate their commercial potential. With substantial capabilities including rapid assessment and comprehensive due diligence, we can provide information and guidance across each phase of your engagement.

In- and out-licensing evaluation

A diverse team with a proven track record

Our clinical, epidemiology, access, and forecasting experts work collaboratively to support holistic and comprehensive in- and out-licensing evaluations, ensuring confident decision-making.

We can support you as part of a long-term strategic process or as tactical support at critical points that may require an independent validation.

Drawing on trusted data sources

We draw upon data sources such as the Oracle Life Sciences Epi Database, Oracle Life Sciences CancerMPact, and Oracle EHR Real-World Data, plus vital medical literature, government databases, and patient surveys. Our experts can deliver accurate, holistic insights into market trends to inform your decisions regarding in- and out-licensing opportunities.

Licensing evaluation for diverse commercial applications

Our experts work across disciplines to support your decision-making around licensing options, enabling you to

  • Assess the overall landscape, competitive market, and market access
  • Quantify the clinical and commercial value of your products
  • Identify and validate partnership or acquisition opportunities
  • Conduct commercial and scientific due diligence
  • Forecast revenue, analyze cash flow, and value assets
  • Map opportunities to organizational strategy and goals

从 Oracle 生命科学开始


订阅博客

了解最新观点和优秀实践,助力临床成功。


获取技术支持

了解技术支持团队联系方式和资源。


关注我们的播客

了解思想领袖关于生命科学行业趋势的真知灼见。


联系我们

联系我们,了解关于临床研究和药物警戒的更多信息。

注:为免疑义,本网页所用以下术语专指以下含义:

  1. Oracle专指Oracle境外公司而非甲骨文中国。
  2. 相关Cloud或云术语均指代Oracle境外公司提供的云技术或其解决方案。